TAG:
cap
Improved 3rd Quarter Performance Posted By National Laboratories
By Robert Michel | From the Volume V No. 16 – November 30, 1998 Issue
Third quarter financial performance at all three national laboratories improved over the same period of 1997. It is an important sign that the three companies are stabilizing their finances. All three national laboratories continue to emphasize cost-cutting as a major corporate priority. That is to …
Kaiser, SBCL To Automate Pap Smear Screening
By Robert Michel | From the Volume V No. 15 – November 9, 1998 Issue
CEO SUMMARY: Two of the country’s largest Pap screen testing organizations are preparing to introduce automated primary screening into their laboratories. NeoPath’s con- tracts with SmithKline Beecham Clinical Laboratories and Kaiser Permanente mark the beginning of a new market cycle…
Kaiser Plans Widespread Use For Pap Technology
By Robert Michel | From the Volume V No. 15 – November 9, 1998 Issue
WITHIN THE HMO INDUSTRY, Kaiser Permanente is highly respected for its thorough research into the clinical efficacy and economic cost of new healthcare technologies. That is the reason why Kaiser’s decision to adopt NeoPath, Inc.’s automated cytology technology…
SBCL Makes System-Wide Commitment To AutoPap
By Robert Michel | From the Volume V No. 15 – November 9, 1998 Issue
SOMEONE ALWAYS HAS TO BE FIRST to adopt new technology. In the case of automated cytology, it will be SmithKline Beecham Clinical Laboratories (SBCL). SBCL and NeoPath, Inc. announced a four-year national agreement between the two companies on October 9 which will e…
Lab Specialists Acquired By Kroll-O’Gara Company
By Robert Michel | From the Volume V No. 15 – November 9, 1998 Issue
CEO SUMMARY: Laboratory Specialists of America has demonstrated a multi-year capability to increase revenues and boost earnings. The merger with Kroll-O’Gara provides it with ample capital to intensify its own acquisition program. One key to Laboratory Specialists’ success is its reco…
Bankruptcy Court Okays Unilab’s Offer For Meris
By Robert Michel | From the Volume V No. 15 – November 9, 1998 Issue
CEO SUMMARY: Meris Laboratories, Inc. is now history. California’s intense competitive market pushed the company into bankruptcy and eventual sale to Unilab, Inc. Even as Unilab moves to consolidate and integrate Meris’ clients and operations into its system, attention is focusing on …
“November 9, 1998 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume V No. 15 – November 9, 1998 Issue
HBO & Co. is the latest to fall victim to consolidation mania. McKesson, Inc. is purchasing HBO for $14 billion in stock. McKesson wants to complement its services as a pharmacy benefits manager with HBO’s extensive health information system capabilities. Combined,…
People Make The Difference
By R. Lewis Dark | From the Volume V No. 14 – October 19, 1998 Issue
IN THIS ISSUE THERE ARE STORIES ABOUT THE SUCCESSES of SmithKline Beecham Clinical Laboratories (SBCL) and UroCor. Each company has a lesson to teach us about developing a business strategy, then making it work in the marketplace. In the case of SBCL, I was astonished to realize tha…
SBCL Inks National Pact With Aetna US Healthcare
By Robert Michel | From the Volume V No. 14 – October 19, 1998 Issue
CEO SUMMARY: As a corporate strategy, SmithKline Beecham Clinical Laboratories wants national contracts and exclusive provider status. The Aetna U.S. Healthcare agreement is SmithKline’s latest victory. Both companies are moving rapidly to implement the contract. In many cities where Ae…
SmithKline’s Strategies Now Delivering Benefits
By Robert Michel | From the Volume V No. 14 – October 19, 1998 Issue
CEO SUMMARY: Business strategy does make a difference. However, it sometimes takes years to appreciate the wisdom of choosing one strategy over another. In the case of SmithKline Beecham’s lab division, the decision to become sole-source provider to the nation’s largest HMOs may event…
CURRENT ISSUE

Volume XXXII, No. 10 – July 14, 2025
This issue is strong on different flavors of enforcement that clinical laboratories, whether they want to or not, will need to contend with. Lab stakeholders provide insights that medical labs need to brace for more action to counter pending test reimbursement rate cuts under PAMA. Also, this issue provides the legal and regulatory landscape for clinical labs’ use of AI and how it evolves with the technology. AI is creating legal uncertainty for clinical labs, especially around data privacy and FDA oversight of AI tools in diagnostics.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized